The ASCO Post

News and views from the world of clinical oncology and hematology

[The ASCO Post @ASCOPost]

📝 #ASCOAI: Ambient #AI scribes are entering oncology workflows, but adoption varies.

New @ClevelandClinic data highlight differences in use among medical oncology, hematology, and radiation oncology clinicians from a large-scale deployment.

🔗️ https://t.co/xZgCfwBup6

[The ASCO Post @ASCOPost]

💻Expanding access to oncology expertise could help address gaps in #CancerCare.

New findings suggest remote expert case reviews can identify opportunities to improve treatment, including for patients in nonurban settings.

🔹Debra Wong, MD | #ASCOQLTY26

https://t.co/tyjNgeDr9p

[The ASCO Post @ASCOPost]

🩸New phase III VERIFY findings highlight rusfertide benefits in patients with #PolycythemiaVera:

⬆️Improved hematocrit control
📉Fewer phlebotomies
⬇️Reduced fatigue and symptom burden

🥼@KuykendallMd | @JCO_ASCO | #MPNsm
🔗 https://t.co/KkzAVpxHH1

[The ASCO Post @ASCOPost]

🚨 #FDAApproval: The @FDA has granted approval for talazoparib (Talzenna) + enzalutamide for adults with HRR-mutated metastatic androgen pathway modulation–naive/sensitive #ProstateCancer.

Approval supported by findings from the TALAPRO-3 trial.

🔗 https://t.co/9EE3mzuycC

[The ASCO Post @ASCOPost]

🏆 @theNAMedicine has elected 100 new members for 2026, recognizing outstanding contributions to medical science, health care, and public health.

🌐 The new class includes 90 U.S. and 10 international members.

Meet the inductees ➡️ https://t.co/GP307bodK6

[The ASCO Post @ASCOPost]

🚭 Financial incentives may improve smoking cessation among patients referred for #LungCancer screening.

In a trial of 3,259 underserved adults, sustained abstinence rates were 8.8% with incentives vs 4.3% with usual care.

▪️@JHartMD | @JAMANetwork
🔗 https://t.co/wOVQ8IhGFs

[The ASCO Post @ASCOPost]

Catch up on the latest #AI in #oncology news:
🔹 @FDA-cleared #BreastCancer risk tool
🔹LLMs in oncology telephone triage
🔹Chatbot improves hereditary #cancerrisk awareness

🎥 Watch this week's brief: https://t.co/iZXoEYIL8k

[The ASCO Post @ASCOPost]

🌎 Geographic disparities limit access to #BreastCancer clinical trials.

A new study found that 76% of U.S. counties had no active TNBC trials, highlighting significant gaps in research access.

🔹Research from @UTMDAnderson & @ASCO

https://t.co/qk8D1GCDB6

[The ASCO Post @ASCOPost]

🧫 The NRG-BR002 trial found that adding metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic #BreastCancer.

▪️Steven J. Chmura, MD, PhD | @JCO_ASCO
https://t.co/oCjUrcgt0G

[The ASCO Post @ASCOPost]

🖥️ #ASCOAI: Personalized PSA monitoring may improve #ProstateCancer follow-up.
An #AI model incorporating PSA kinetics, clinical data showed promising accuracy in identifying recurrence risk after radiotherapy. #ASTRO26
➡️External validation is underway
🔗 https://t.co/yqtSSXjkWy

[The ASCO Post @ASCOPost]

📄Experts call for stronger quality-of-life reporting in adjuvant #Cancer trials.

New recommendations emphasize measuring clinically meaningful deterioration, duration, & recovery rather than relying on average scores.

🔸Ian Tannock, MD | @TheLancetOncol
https://t.co/880RNyne5M

[The ASCO Post @ASCOPost]

🧠 Updated phase I data show promising survival with bivalent #CARTcell therapy in recurrent #Glioblastoma.

Among 18 patients, the median OS was 12 months, with no delayed-onset or unexpected toxicities observed.

▪️@StephenBagleyMD | #ASCO26

🔗 https://t.co/HhC2fhiBz0

[The ASCO Post @ASCOPost]

📰 Top stories in the October issue of The ASCO Post:

🔹Bivalent #CARTcell therapy in recurrent #glioblastoma
🔹B7-H4–targeted ADCs in #ovariancancer
🔹Evolving treatment options for relapsed #DLBCL
🔹#GLP1 RAs & #BreastCancer risk

Explore the issue ➡️ https://t.co/rmcO6KF6eA

[The ASCO Post @ASCOPost]

📱 #ASCOAI: Personalized digital education may strengthen hereditary #Cancer counseling.

The AYA-RISE chatbot improved risk comprehension in young patients using guideline-based content and predefined conversations, not generative #AI.

Learn more ➡️ https://t.co/2TnDMzFb5n

[The ASCO Post @ASCOPost]

🫁 Claudia Henschke, PhD, MD, helped transform #LungCancer screening through pioneering research on early detection with low-dose CT.

@RajaFlores reflects on her extraordinary career, scientific legacy, and personal impact.

Read the full dedication 👉 https://t.co/f0zr4gGqIG

[The ASCO Post @ASCOPost]

🚨 #FDAApproval: The @FDA has granted traditional approval to pembrolizumab (Keytruda) and Keytruda Qlex for previously treated, unresectable or metastatic TMB-H solid tumors (≥13 mut/Mb) with no satisfactory alternatives.

🔗 https://t.co/tBcukKbx6g

[The ASCO Post @ASCOPost]

🩻 The phase 3️⃣ RT CHARM trial found that a 3-week course of postmastectomy radiation therapy was safe and noninferior to a 5-week course for reconstruction complications in women with #BreastCancer.

🔹Matthew Poppe, MD of @huntsmancancer | @JCO_ASCO

🔗 https://t.co/xUM5250CVo

[The ASCO Post @ASCOPost]

🫁 At today's 50th I-ELCAP Conference, @AltorkiNasser discussed how early #lungcancer detection is transforming surgical management. By identifying cancers sooner, patients may have more opportunities for surgical resection and potentially curative treatment.

#IELCAP

[The ASCO Post @ASCOPost]

🩸The treatment landscape for relapsed/refractory #DLBCL continues to evolve.

At the @NCCN Hem Congress, Jeremy S. Abramson, MD, MMSc, discusses how #CARTcell therapy, bispecific antibodies, and novel combinations are reshaping treatment sequencing.
🔗 ️ https://t.co/01rBapgtkH

[The ASCO Post @ASCOPost]

🥼#ASCOAI: A scoping review identified 5 studies of intraoperative #AI decision support, revealing significant gaps in clinical validation, ethical governance and regulatory reporting.

☑️ Findings highlight challenges in translating AI into surgical care

https://t.co/h3qca5gYM1